Medicinal compositions containing anti-Fas antibody
A composition and antibody technology, applied in the field of new pharmaceutical compositions, can solve problems such as lack of understanding of synergy
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0142] As the anti-Fas antibody, the anti-human Fas monoclonal antibody HFE7A or CH11 (manufactured by the Institute of Medical Biology, Ltd.) described in European Patent Publication No. 0909816 was used.
[0143] The human lymphocyte cell line HPB-ALL (refer to Morikawa, S., et al. (1978) Int. J. Cancer 21, 166-170) was cultured in RPMI 1640 medium containing 10% FCS (manufactured by Gibco B.R.L.), Cultivate at 37°C in the presence of 5% carbon dioxide for 3 days, and then inject 50 μl (2.5×10 5 cells / 50 μl). Then, 50 µl of RPMI medium containing methotrexate (manufactured by Sigma) and anti-Fas antibody (CH11 or HFE7A, serially diluted 3 times from 0.001 mg / ml) was added to each well, and cultured at 37°C.
[0144] The plate to which CH11 was added as an anti-Fas antibody was directly incubated overnight at 37°C. On the other hand, in the culture plate supplemented with HFE7A, cells were washed with RPMI medium after culturing for 1 hour, and then 100 μl / well of an anti-m...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com